Safety and tolerability of docetaxel with cyclophosphamide for early breast cancer

Hidetaka Kawabata, Tsuguo Iwatani, Rie Makuuchi, Daishu Miura, Noriyuki Suzuki, Hideki Nakazawa

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


The US oncology 9735 study showed the superior result of TC (docetaxel/cyclophosphamide) over AC (doxorubicin/ cyclophosphamide), and now TC has been widely adopted for the treatment of early breast cancer. But in Japan there are few data on the safety and tolerability of this regimen. From January 2007 to April 2009, we treated 51 early breast cancer patients with TC in our hospital, and we summarized safety and tolerability profile, including hematologic toxicity and nonhematologic toxicity. Our patients experienced more febrile neutropenia (25.5%) compared with the original USO 9735 result (5%). This might be because we did not use prophylactic oral antibiotics. Skin toxicity was sometimes troublesome, including 3 cases (5.9%) of grade 3 skin rash. Toxicity assessment showed more asthenia, edema, neuropathy and myalgia, as is well known. Finally, we recommend prophylactic oral antibiotics, steroid premedication from the day before treatment and skin moisture, which may minimize the toxicity.

Original languageEnglish
Pages (from-to)835-839
Number of pages5
JournalJapanese Journal of Cancer and Chemotherapy
Issue number5
Publication statusPublished - May 2010
Externally publishedYes


  • Breast neoplasms
  • Docetaxel
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Safety and tolerability of docetaxel with cyclophosphamide for early breast cancer'. Together they form a unique fingerprint.

Cite this